BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22

• 

  Immuno-oncology

  Four Therapies Hanging On in Troubled TIGIT Space

  TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and shuttered businesses. Here are five biopharma players staying alive with differentiated candidates against the once promising immuno-oncology target.

  July 7, 2025

   · 

  9 min read

   · 

  Tristan Manalac
• 

  Layoffs

  HHS Cuts and Rehires by the Numbers: What We Know About Kennedy’s Overhaul

  Despite rehiring hundreds of FDA, CDC and NIH employees, the Department of Health and Human Services is still a skeleton of its former self under Health Secretary Robert F. Kennedy Jr.

  July 7, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Sponsored

  Bridging the Gap: Aligning Drug Development with Real-World Clinical Needs in Oncology

  In the United States, only 31.4 % of phase II/III clinical trials in oncology are successfully completed¹. The causes of this dramatic economic and time-consuming loss are, among others, protocol design and patient recruitment challenges.

  July 7, 2025

   · 

  6 min read
• 

  Approvals

  KalVista Wins OK for First On-Demand Hereditary Angioedema Pill

  Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due to resource constraints and reports surfaced that Commissioner Marty Makary tried to have the application rejected.

  July 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  How AI and Genetics Could Restore Public Trust in Pharma

  Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical industry’s reputation amid mounting criticism.

  July 7, 2025

   · 

  6 min read

   · 

  Allan Gobbs
• 

  Drug Development

  5 Second-Half Biopharma Milestones To Watch

  After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in 2025, according to Jefferies.

  July 7, 2025

   · 

  8 min read

   · 

  Tristan Manalac
• 

  Artificial intelligence

  Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero

  The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in aging-related diseases. Chugai will then develop antibody-based drugs based on the findings.

  July 7, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Immunology and inflammation

  Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans

  A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s Ayvakit, which Leerink analysts said does not sufficiently treat all patients.

  July 7, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• Press Releases

  Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials

  July 7, 2025

   · 

  5 min read
• Press Releases

  Public Advisory - NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug

  July 7, 2025

   · 

  2 min read